|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
The 'European disease'
Robert Goldberg, Ph.D., is a senior fellow at the Manhattan Institute who writes widely on health care issues. In this op-ed, he argues that policymakers who advocate prescription drug-importation and price controls threaten U.S. leadership of the global biopharmaceutical industry.
…European companies that moved here to escape price controls [in Europe] are already preparing to move again, to Asia, if Congress [passes the Pharmaceutical Market Access Act, legalizing drug importation].
Already, one CEO, Sir Tom McKillop, has said that he would relocate his pharmaceutical company Astra Zeneca from the U.S. to India or China if Congress legalizes importation. Mckillop said that "there is real danger for the United States to catch the European disease…Europe lost its prominent position in pharmaceutical research because of policies that favored parallel trading of drugs between states."
|home spotlight commentary research events news about contact links archives|